Ovid Therapeutics (OVID) Research & Development (2016 - 2026)

Ovid Therapeutics (OVID) has reported Research & Development for 11 consecutive years, with $10.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 54.01% year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2026 stood at $33.6 million (up 24.89% YoY), and the FY2025 full-year result was $25.6 million, down 30.42% from the prior year.
• Research & Development declined to $10.0 million in Q2 2026 per OVID's latest filing, from $11.2 million in the prior quarter.
• Across five years, Research & Development topped out at $12.6 million in Q2 2024 and bottomed at $5.2 million in Q3 2022.
• Historically, Research & Development has averaged $7.6 million across 5 years, with a median of $6.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Research & Development sank 54.83% in 2022, then soared 109.73% in 2024.
• Over 5 years, Research & Development stood at $5.6 million in 2022, then surged by 91.53% to $10.6 million in 2023, then sank by 44.34% to $5.9 million in 2024, then advanced by 11.24% to $6.6 million in 2025, then soared by 51.12% to $10.0 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $10.0 million, $11.2 million, and $6.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.